Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Life Science Startup Investors in United Kingdom in November 2024

Last updated: Nov 2024 A list of 50 angel investors and VC (Venture Capital) funds that invest in Life science startups based in United kingdom. We rank investors based on the number of investments they made in Life science companies from United kingdom. We update this investor list every month.

Top 50 Life Science Startup Investors in United Kingdom in November 2024

Investor	Life Science United Kingdom investments
Parkwalk Advisors	17
Oxford Science Enterprises	14
UK Innovation & Science Seed Fund	13
SOSV	13
Jonathan Milner	8
Development Bank of Wales	8
24 Haymarket	7
Oxford Science Enterprises	7
Sofinnova Partners	7
Syncona Partners LLP	7
GM&C Life Sciences Fund	7
Archangels	7
Newable Private Investing	6
Scottish Investment Bank	6
Scottish Enterprise	6
Angels in MedCity	6
Selvedge Venture	6
APEX Ventures	5
Epidarex Capital	5
Deepbridge Capital	5
Future Planet Capital	5
Verve Ventures	5
IQ Capital	5
AlbionVC	4
O2h Ventures	4
Formic Ventures	4
Kindred Capital	4
Octopus Ventures	4
Nadav Rosenberg	4
Playfair Capital	4
Angels 5K	4
Mercia Fund Managers	4
Dementia Discovery Fund	4
SR One	4
11.2 Capital	4
Oxford Capital	4
Maven Capital Partners	3
Northern Gritstone	3
Google Ventures	3
Molten Ventures	3
Discovery Park	3
Stefano Bernardi	3
Acequia Capital (AceCap)	3
Techstart Ventures	3
Wren Capital	3
Calculus Capital	3
Hoxton Ventures	3
R42 Group	3
Nina Capital	3
Beltrae Partners	3

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Evoralis — Utilise Our Innovative Enzymes to Efficiently Recycle Plastics Into High-Quality Raw Materials
Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series B
United Kingdom, United States, Finland

Portfolio highlights

natcap — We support the world's leading companies to prioritise, measure and act on nature impacts, dependencies, risks and opportunities.
FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Iota Sciences — Discover automated single-cell handling tools and related services to accelerate your route to breakthrough discoveries in cell biology

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

HonuWorx — HonuWorx is a technology company providing autonomous systems aimed at lowering both expenses and the environmental impact of operating robotic systems. The company's software technology is an edge-cloud architected communications and control platform that enables geographically distributed stakeholders to see data, collaborate, supervise, andcontrol robotic systems that are beyond line-of-sight.
Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and, in 1998, founded Abcam with David Cleevely and Professor Tony Kouzarides. Jonathan is a Non-Executive Director of Horizon DiscoveryGroup plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP. Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Series B
United Kingdom, United States, Canada

Portfolio highlights

Clock Bio — Clock Bio operates as a biotech company, that develops novel regenerative medicines.
LIfT BioSciences — LIfT BioSciences is a socially-minded Biotech start-up that develops a portfolio of potentially life-saving immuno-oncology cell therapies for different solid tumors using its innate immunity platform. Its goal is to create a Cell Bank with the potential to cure cancer, using Leukocyte Infusion Therapy.LIfT BioSciences was founded in 2016 andheadquartered in London, England.
Shift Bioscience — Explore cutting-edge simulation-guided cell rejuvenation techniques aimed at combating aging-related diseases.

Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

PlantSea — PlantSea manufactures and develops sustainable products using seaweed and aquaculture materials. It offers bioplastics items as biodegradable alternatives. PlantSea is based in Gaerwen, England.
Menna — Be smarter about money and grow faster with Menna. Take control of your business finances today!
Llusern Scientific — Llusern specialises in rapid and affordable near-patient and POC molecular diagnostics developed to detect bacterial and viral infections.

24Haymarket is an investment network which included several highly-experienced private equity and venture capital investors, seasoned entrepreneurs, and senior operators. Investing up to £5 million in growth companies in the UK and Europe. They invested their own capital in direct alignment with entrepreneurs and actively support their growthagenda and join the board of the companies in which they invest. Since inception in 2011, 24Haymarket has invested in more than 50 high-growth businesses.

Investment focus

Health Care, Software, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

myGwork — The global recruitment & networking hub for LGBTQ+ professionals. Find jobs in lesbian, gay, bisexual and transgender friendly organisations. Grow your LGBTQ+ professional network. Read the latest LGBTQ+ professional news.
Previsico — Previsico is a spinOut company from Loughborough University specialising in modelling flooding in real-time, using weather predictions to make street-level flood nowcasts and forecasts. The company's mission is to be the leading global provider of cutting-edge flood prediction that saves lives and livelihoods.Its FloodMap Live producesround the clock street-level flood risk predictions and analytics. Uniquely, these are continuously modelled and updated using a combination of different weather forecasts. This allows the company to map the likelihood of short and long-term surface water events in real-time to the street level.
Huq Industries — The leading monitoring platform for footfall, dwell, catchment and traffic flows valued by government, retail and real-estate. Used by 50+ councils!

Investment focus

Biotechnology, Health Care, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

natcap — We support the world's leading companies to prioritise, measure and act on nature impacts, dependencies, risks and opportunities.
FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Iota Sciences — Discover automated single-cell handling tools and related services to accelerate your route to breakthrough discoveries in cell biology

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Series C
France, United States, United Kingdom

Portfolio highlights

deepc — The Radiology AI Platform - Your effortless access to AI
Genespire — Genespire is a biotechnology company focused on the development of transformative gene therapies for patients affected by genetic diseases, particularly primary immunodeficiencies and inherited metabolic diseases.
Micropep Technologies — Micropep Technologies developes a non-GMO new generation of bioherbicides and biostimulants. Micropep, founded in 2016 in Toulouse, focuses on bioherbicides and biostimulants. The company uses plants’ natural molecules, called “micro-peptides”, to temporarily control expression of their genes and regulate plant growth but leaving their DNA intact.The company currently works on four development programs: germination, flowering, growth, and weed control.

Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.

Investment focus

Biotechnology, Health Care, Medical
Series A, Series B, Seed
United Kingdom, United States, Switzerland

Portfolio highlights

iOnctura — Our mission is to develop high impact, low disruption therapies that extend healthspan. We do this by disrupting the dynamic interplay at the heart of the
Purespring Therapeutics — Purespring Therapeutics is an AAV gene therapy company focused on the kidney globally.
Resolution Therapeutics — Resolution Therapeutics is a biopharmaceutical company developing macrophage cell therapy to treat chronic diseases.

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
1inhaler — 1inhaler operates as a developer of drug delivery device.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology

Speak with our Entrepreneurship and Investment teams, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.

Angels in MedCity is a partnership between MedCity, London Business Angels and Angels4LifeSciences. The programme aims to introduce new people to investing and investing in the healthcare/life sciences sector via investor workshops and introduce business angels to investment opportunities from highly-selected and trained companies.With aparticular focus on drug therapies, digital health and medical device technologies, Angels in MedCity brings potential investors together with life sciences experts in a programme aimed at both people who are new to investing and experienced investors who have little or no experience in the life sciences sector. The aim is to build investor understanding in the life sciences sector and support life sciences companies to gain funding to commercialise their ideas.Angels in MedCity has created a community of investors supported through a programme of investor workshops. Using case studies and tips from experienced investors in the field, the workshops explain how to identify and structure a good deal in the life sciences sector, as well as provide expert advice on tax breaks and legal issues.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Angel
United Kingdom, United States

Portfolio highlights

Atelerix — Discover Atelerix's hypothermic hydrogels for eco-friendly, reliable cell preservation and ambient temperature shipping. Ensure fresh, viable cell samples today.
Clustermarket — The intuitive lab management system for all academic research facilities and industrial laboratories that need to efficiently manage equipment bookings.
DynamX Medical — DynamX Medical has developed a reliable and inexpensive precancer screening system for rapid tissue biopsy analysis that can be operated point-of-care by nurses.

Selvedge Venture operates as a venture capital firm investing for impact in age-related medical conditions.

Investment focus

Health Care, Biotechnology, Life Science
Seed, Pre-Seed, Series A
United Kingdom, Singapore

Portfolio highlights

Mesh Bio — Mesh Bio is a digital health startup that is transforming chronic disease management through predictive analytics. Mesh Bio works with healthcare providers and stakeholders to provide innovative solutions that transform health screening and disease management. They translate clinical data and numbers into actionable insights that help patientsbetter manage their health, lifestyle and disease risks.
Ochre Bio — Ochre Bio is developing therapies for the biggest liver health challenges.
BIOS — BIOS Health is unlocking the potential of the nervous system in treating chronic disease by using AI-powered neural interfaces that can automatically read and write neural signals.

APEX Ventures is a deep-tech and medical-focused venture capital firm.

Investment focus

Artificial Intelligence, Health Care, Software
Seed, Series A, Funding Round
Germany, United Kingdom, Austria

Portfolio highlights

Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.
TriLite Technologies — The world's smallest projection displays from TriLite take laser beam scanning technology to the next level, for augmented vision as light as the eyewear of today.
CardiaTec Biosciences — CardiaTec is a digital biotechnology venture combining the power of AI and expert talent to redesign cardiovascular drug discovery to deliver the next generation of therapeutics

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

AI-Sight — AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

Brilliant Ideas. Brilliant People. Brilliant Minds.

Investment focus

Biotechnology, Health Care, Software
Funding Round, Seed, Convertible Note
United Kingdom, United States, Canada

Portfolio highlights

44.01 — We offer a permanent CO2 storage solution using the natural power of mineralisation
Ikarovec — Ikarovec is developing novel gene therapies to treat major ophthalmic indications.
Wittaya Aqua — A better approach to aquaculture management

Verve Ventures has invested in more than 140 science and technology startups. We support visionary and resilient entrepreneurs from day one and are a reliable partner for the entire journey. We typically invest EUR 1-3m in early as well as later stage rounds of European high tech startups.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Series B
Switzerland, Germany, France

Portfolio highlights

Otoqi — Otoqi is a vehicle delivery platform that develops connected services and logistics solutions for the automotive professionals.
Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
Somagenetix — Somagenetix is a new firm that wants to be a leader in gene therapy by developing first-in-class treatments for phagocyte-related illnesses. Somagenetix's mission is to use genetically modified phagocytes to treat patients suffering from immunodeficiency, neurodegeneration, and cancer with brain metastases.

IQ Capital is a Cambridge & London-based VC firm that invests in ‘deep tech’ companies capable of dominating their respective markets on a global scale. Initial investments at Seed and Series A range from £0.5m to £10m, with capacity for follow-on investment up to £30m through the Growth Fund. The team has achieved over 30 exits including toApple, Huawei, Google and Oracle.

Investment focus

Software, Artificial Intelligence, Machine Learning
Seed, Series A, Funding Round
United Kingdom, United States, The Netherlands

Portfolio highlights

NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
Vsim Technology — Experience the power of next-generation physics simulations with Vsim. Our cutting-edge technology provides realistic and accurate simulations for various industries.
BMLL Technologies — BMLL Technologies Ltd. operates cloud based technology platform that offers machine learning and inference framework for common limit order book problems.

AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which isauthorised and regulated by the Financial Conduct Authority.

Investment focus

Software, Health Care, Information Technology
Series A, Funding Round, Seed
United Kingdom, United States, France

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
tem. — In a few simple steps we can manage your renewable energy needs forever.
Infact Systems — Infact Systems is a company that focuses on bringing affordability and credit information into the 21st century. They facilitate the sharing of real-time, contextual data, primarily in the banking industry. Their mission is to increase responsible financial behavior by providing real-time data for modern credit. They offer integration andcustomization services for HPZone, particularly in terms of connecting with external laboratory systems. Infact Systems also provides services to help women take control of their finances.

Focused on seeding early stage biotech therapeutics and related AI opportunities. The fund will invest in companies qualifying under EIS and covering novel...

Investment focus

Biotechnology, Health Care, Pharmaceutical
Seed, Series A, Pre-Seed
United Kingdom, Hungary

Portfolio highlights

Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
ViaNautis — Precision Solutions
Pencil Biosciences — Next Generation Genome Editing Tool

Formic Ventures is a diversified venture capital firm that makes early-stage investments in biotechnology startups focused on human longevity as well as technology startups and companies that make human lives more meaningful.

Investment focus

Biotechnology, Health Care, Artificial Intelligence
Seed, Series A, Funding Round
United States, United Kingdom, Hong Kong

Portfolio highlights

Turn.bio — Turn Biotechnologies is a Stanford spinout developing therapies to effectively return mature differentiated cells to a dramatically younger state leaving their differentiated identity unaltered.Turn Biotechnologies surpasses traditional approaches based on single gene/pathway manipulations and tackles the multifaceted manifestation ofcellular age at the organ, tissue, and organismal level to extend the healthspan of people. As a result, age is reset by epigenetically reprogramming cells.
cheMastery — Echo handles repetitive tasks with accuracy and precision, allowing your chemists to tackle high-value challenges.
Sampling Human — The mission of Sampling Human is to couple health related decisions to their effects at the single cell level. It is inspired by the founders’ academic and professional efforts to extend what is measurable and to derive what must be measured.The human body is a complex system that cannot be quantified exhaustively or heuristically. Clinicaldiagnosis today is an imprecise art. On average, diagnosis of rare diseases is 5 years delayed with 50% of delays impacting the outcome. Misdiagnosis is far too common with a 66% likelihood of disagreement between experts. We are stuck with symptoms based medicine.The nature of physiological data is to blame. Decisions today are based on fuzzy variables (tired, drowsy, weak, tingling, itchy, etc). Better decisions will require precise knowledge regarding the fundamental physiological units of our bodies, CELLS.

A new model for Venture Capital where every founder we back becomes a co-owner of the fund

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Series B
United Kingdom, Israel, United States

Portfolio highlights

Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
Dunia Innovation — Catalysing the energy transition.
Shift Bioscience — Explore cutting-edge simulation-guided cell rejuvenation techniques aimed at combating aging-related diseases.

We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Desia — Desia provides advanced AI applications for productivity, automation, and analytics for financial services.
NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
Stema — It serves as a platform for hiring engineers

Nadav leads Taboola’s expansion and operations in Europe and Australia.Prior to joining Taboola, Nadav was a member of the founding team of Groupon UK & IR, taking part in building and managing Groupon’s business in the UK.Before joining Groupon, Nadav worked as a strategy consultant with McKinsey & Company in London.Nadav isbased in London and holds an MBA from INSEAD, France.

Investment focus

Biotechnology, Artificial Intelligence, Pharmaceutical
Seed, Pre-Seed, Series A
United Kingdom, Israel, Singapore

Portfolio highlights

thymia — Making mental health as objectively measurable as physical health.
Exogene — Exogene is a biotechnology company accelerating the discovery of T-cell-receptor(TCR)-based cancer immunotherapies for solid tumours by combining deep learning and high-throughput TCR-antigen screening. Exogene is building a computational platform to quickly and inexpensively identify new tumour targets shared across cancer patients, as well assafe and effective TCRs against these tumour targets for therapeutic application. Their mission is to develop better TCR-based immunotherapies, faster and at a fraction of the cost.
Loops — With Loops causal insights you can identify your biggest opportunities to maximize your KPIs... try the Loops way

Playfair is a generalist VC fund with a contrarian approach to pre-seed technology investing. Based in London, Playfair invests across the UK and Europe with an intentionally high conviction, low volume approach: making 6-8 investments a year and preserving time, capital and resource to help companies post-investment. Playfair has backed 70+companies across two funds including Thought Machine, Andela, Mapillary, Recycleye and Orca AI.

Investment focus

Software, Artificial Intelligence, E-Commerce
Seed, Series A, Funding Round
United Kingdom, United States, France

Portfolio highlights

Recurse ML — Streamline your development with Recurse, enabling seamless code maintenance with just a single command.
NetFabric — NetFabric is developing a next-gen network observability platform
Passionfruit — Join hundreds of the best startups around the world and use Passionfruit to hire freelance marketing specialists on-demand.

Southern Angel Investors Club, combining Surrey investors Club & Angels 5K, are entrepreneurs who understand what new businesses need.

Investment focus

Biotechnology, Software, Medical
Seed, Funding Round, Angel
United Kingdom

Portfolio highlights

Celixir — Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchersto discover breakthrough medicines that aim to change the standard of medical care for patients.
Novastone Media — With its unique asymmetric technology, novastone puts you directly where your clients want to talk to you.
Geektastic — Geektastic guarantees hiring teams only meet high calibre candidates. Our technical code challenges quickly identify the most talented software engineers.

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Hungary

Portfolio highlights

Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
MGISS — Independently advising on the smarter use of Geospatial data, technology and the digital transformation of field operations.
Workbuzz — Give your Everyday Heroes a voice with employee surveys. Our flexible and simple survey platform reaches all employees, wherever they are. Book a demo now!

SV Health Investors is a specialist healthcare fund manager, investing across multiple stages and sectors. Our goal is to transform healthcare one investment at a time.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Seed, Funding Round
United States, United Kingdom, Israel

Portfolio highlights

AstronauTx — AstronauTx is a UCL spin-off, will develop medicines designed to reset the behaviour of astrocytes.
Sudo Biosciences — Sudo Biosciences is a biopharmaceutical company committed to developing cutting-edge medications that are unmatched in their class.
Montara Therapeutics — Montara Therapeutics is a precision-medicine neuroscience biotech startup improving safety and efficacy of therapies for people with neurological diseases

SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, Canada

Portfolio highlights

Asceneuron — Asceneuron develops effective therapeutics for orphan tauopathies and Alzheimer’s disease. By focusing on areas of high unmet medical need, Asceneuron aspires to become a leading biotech company specialized in small molecule drug discovery for neurodegenerative diseases.Tauopathies are currently untreatable neurodegenerative diseases thatrapidly progress towards debilitating conditions. The appearance of deposits of the microtubule-associated tau protein as e.g. neurofibrillary tangles in neurons of the brain is a common feature of tauopathies that is shared with Alzheimer’s disease. Neuronal tau deposits are known to be a major contributor to neurodegeneration and mutations in the tau gene are causative of the tauopathy fronto-temporal dementia and parkinsonism linked to chromosome 17 (FTDP-17).Due to increasing life expectancy, Alzheimer’s disease is viewed as one of the largest healthcare problems of this century, imposing a major economic burden on societies in the Western and developing world. Current treatment options provide limited benefits supporting the urgent need for more efficacious and better tolerated medicines that address symptomatic relief as well as disease progression.
Renalys Pharma — Renalys Pharma is a private, late-stage clinical biopharmaceutical firm in Japan dedicated on developing new therapies that address unmet needs in the management of renal illness in Japanese and Asian patients.
Nomic — Nomic develops a proteomic technology platform designed to understand, detect, and treat diseases with DNA nanotechnology. NPlex's platform and research provides cost-effective measurement of protein data with sample, fits seamlessly within industry cytometers for high-throughput analysis, and development of custom protein panels.It allowsnanotechnology developers and businesses to bring improvement in existing instrument, workflow, and bring automation in the system.

In physics, 11.2 km/s is the escape velocity from Earth's gravity. They focus on emerging technologies such as AI, cybersecurity, robotics, quantum, new space, computational therapeutics, synthetic biology. They believe great people are leading indicators of a company's success. 11.2 Capital’s technical background, operationalexperience, and a strong network of amazing advisors and international partners particularly in Asia deliver a unique set of resources to entrepreneurs. While they are happy to help companies across the full range of early-stage company questions, areas where they concentrate include technical recruiting, partnerships (OEM and distribution partnerships for smart hardware companies, data partnerships for data-driven healthcare companies), customer introductions (CISO introductions for security companies, provider introductions for healthcare companies), and follow-on financings.

Investment focus

Software, Information Technology, Biotechnology
Seed, Series A, Series B
United States, Canada, United Kingdom

Portfolio highlights

Noetik — Noetik is an AI-native biotechnology company. Our mission is to leverage advanced machine learning methods to discover and develop cancer immunotherapies.
Mantle — Mantle is an engineering and manufacturing company that has developed metal 3D printing technology to produce high-resolution parts that meet the critical needs of applications from automotive and aerospace to consumer product design and prototyping.
Coalesce Automation — Coalesce is the only data transformation tool built for scale. Evolve your transformations and empower your entire data team.

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Investment focus

Software, Health Care, Biotechnology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Ittybit — Ittybit is a API that enables users to handle rich media in applications. It provides developers with basic techniques for uploading, storing, transforming, and extracting data from video, music, and image files.
HealthKey — HealthKey is a platform that connects employers and insurers with health providers.
Noggin HQ — The next generation of credit referencing is coming. Look busy.

Maven is one of the UK's leading private equity and investment firms. We provide essential capital and expertise to help businesses unlock their potential.

Investment focus

Software, Information Technology, SaaS
Funding Round, Series A, Seed
United Kingdom, United States, Germany

Portfolio highlights

Novatus Global — Enabling firms to Ensure Accurate, Complete, and Timely transaction reporting across all regimes with our award-winning reporting platform, En:ACT.
Connected Data — Connected Data | Data Enabled Debt Management
Corporate Modelling — OPX is our award-winning business optimisation software which will transform your business and improve your productivity.

Northern Gritstone is an investment firm focused on investing in advanced materials, energy, health technology and cognitive computation.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Series D
United Kingdom

Portfolio highlights

Phagenesis — Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.
MicroLub — MicroLub produces a fat replacement for lower-calorie plant-based diets. It is cutting-edge innovation to the next generation of protein technology, creating exclusive ingredient solutions that significantly minimize molecular friction.
Cavero Quantum — A quantum-safe symmetric cryptographic key solution built to last

GV supports innovative founders moving the world forward.

Investment focus

Software, Health Care, Biotechnology
Series A, Series B, Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Infinitus Systems — Infinitus Systems offers Voice Robotic Process Automation (VoiceRPA) software for businesses in the healthcare industry.
Speakeasy — Create great integration experiences for your APIs: native-language SDKs, Terraform providers, and friction-free docs.
PeopleOne Health — PeopleOne Health provides world-class healthcare that seamlessly blends treatment and prevention, leading to significant savings for employers and employees by keeping people healthier. This is the next generation of value-based primary care. Employers save up to 30% on healthcare costs and enhance employee recruiting and retention. Employees getaccess to an award-winning health benefit at no cost, including a team of top-tier doctors and healthcare professionals. Leading employers and thousands of members trust PeopleOne Health and rate their customer satisfaction an excellent 90+ NPS (exceeding the healthcare industry average of 35). Discover more at peopleonehealth.com.

Molten Ventures is a venture capital company. They invest in software, telecoms, electronics, the internet, MedTech, and cleantech services. They support visionary entrepreneurs who will invent the future.

Investment focus

Software, Information Technology, Financial Services
Series A, Series B, Funding Round
United Kingdom, United States, Germany

Portfolio highlights

Aktiia — Founded in Switzerland in May 2018 out of a passion to turn insights into action in the fight against hypertension, Aktiia’s groundbreaking medical technology provides people and their physicians comprehensive insights into blood pressure patterns that will inform the diagnosis and management of hypertension. Now available in the United Kingdom,Aktiia has received its CE Mark as a Class IIa medical device - signifying that the device has been assessed to meet high safety, health and environmental protection requirements in Europe. To learn more, visit Aktiia.com.
FintechOS — FintechOS extends your core, letting you innovate banking and insurance products, digital journeys, and back-office workflows without the cost or risk.
Anima — Anima's online patient triage speeds up the clinical workflow 10x and allows providers to deliver the right care for patients within 24 hours.Millions of patients with serious problems are missed and die every year because there isn’t adequate information flow between medical appointments. Patients submit their problems and requests onAnimainstead of waiting for an appointment, and Anima sends an actionable report to their provider with trends, risks and recommendations.

Discovery Park is a thriving UK science park offering state-of-the-art lab space to rent and modern offices in Kent.

Investment focus

Life Science, Biotechnology, Biopharma
Pre-Seed, Seed
United Kingdom

Portfolio highlights

BugBiome — Reinventing Pest Control. Protecting People, Animals, and the Planet
BoobyBiome — BoobyBiome harnesses breast milk microbiome science to develop products to improve infant health

Stefano Bernardi is the Investment Director, Climate at Fondazione ENEA Tech.

Investment focus

Software, Biotechnology, Artificial Intelligence
Seed, Pre-Seed, Funding Round
Italy, France, Norway

Portfolio highlights

Freatic — We bridge the gap between individuals with untapped knowledge and actors who can take advantage of these opportunities.
Eden Bio — Eden Bio is a biotech using machine learning to guide the genetic engineering of microorganism strain optimisation, improving protein yield.
CaSRevolution — A novel disease-modifying approach against neurodegeneration

We are a leading early-stage investment platform. We are at the center of a global ecosystem that attracts and fuels the technical founders and product teams building the next wave of global businesses.

Investment focus

Software, Artificial Intelligence, Information Technology
Seed, Series A, Pre-Seed
United States, United Kingdom, Switzerland

Portfolio highlights

Sloyd — 3D modeling has never been easier. Select a generator, tweak it, done. Generate with realtime in the Sloyd Webapp or SDK.
Legion Health — Legion Health is building the infrastructure for health care organizations to scale their virtual mental health offerings.
ExpressionEdits — Redefining the status quo of protein expression

Techstart Ventures is a leading investor of seed capital across Scotland and Northern Ireland. they are a trusted partner to ambitious founders on their journey to success.

Investment focus

Software, Information Technology, Health Care
Seed, Pre-Seed, Funding Round
United Kingdom, Ireland

Portfolio highlights

INQDATA — INQDATA are a cloud-based data solutions provider who tranform the way financial institutions access and manage their market data. Our seamless integration makes it as easy as possible for clients to access the data they want, when they want it - all in their technology and tooling of choice.
Saltroad — Get matched with an experienced HCPC Speech and Language Therapist based on your child's needs, your budget and your schedule. Loved by parents & children.
Sensoteq — We specialise in wireless sensor solutions for remote machine health monitoring. Sensoteq's technology enables predictive maintenance of industrial applications, preventing costly downtime and increasing efficiency.

Wren is an angel investor in science, engineering and software. They founded Wren in 2011 and have invested in 50 companies so far.Wren is well known in the early stage investment community and has co-invested with a wide range of both angel and institutional investors. From software and semiconductors to genome editing, and from medical devicesto satellites, they are interested in sectors where technical ingenuity and hard work can produce long term value. They look for people with a deep understanding of their markets. The founders they invest in are smart and they get things done.Wren typically invests £50,000 to £200,000 per funding round. Difficult problems take time to solve, so they are patient with their investments. Their aim is to get deals done and they take a pragmatic approach to doing so.

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom

Portfolio highlights

Spotta — Spotta's smart pest systems help pest control monitor and identify pests. Solutions for hospitality, care homes, agriculture, farming and forestry.
PharmEnable — At PharmEnable Therapeutics we access the inaccessible. We are re-imagining small molecule therapeutics through AI.
Bastion Therapeutics — Bastion Therapeutics - Enhancing Tregs To Restore Balance In Inflammatory Disorders Treg cell therapy for inflammatory disorders and autoimmune diseases.

At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Series A, Seed
United Kingdom, United States, Ireland

Portfolio highlights

WorkL — WorkL provides all the resources you need in one location to find employment, advance your career, connect with others, and communicate.
Tagomics — Tagomics transform disease diagnosis through comprehensive multitopic profiling.
MIP Discovery — MIP Diagnostics develop and manufacture molecularly imprinted polymers (nanoMIPs) that act as synthetic alternatives to antibodies for IVD and other industries.

Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.

Investment focus

Artificial Intelligence, Information Technology, Software
Seed, Series A, Funding Round
United Kingdom, United States, Canada

Portfolio highlights

CuspAI — CuspAI is a revolutionary AI startup that is developing a platform for next-generation materials to address global sustainability and renewable energy concerns. CuspAI uses cutting-edge generative AI, deep learning, and molecular simulation to accelerate the material design process. Their platform works similarly to a search engine for materials,allowing users to request certain properties for new materials on demand.
Malted AI — Malted AI is a developer of a low-code platform enables enterprises to build and deploy large language models-enabled applications at scale, using distillation to inject domain-specific knowledge into smaller, focused models, trained on proprietary data in a secure environment.
PACT — PACT designs Elegant materials produced in tune with the planet earth. It create revolutionary, sustainable biomaterials using the earth's resources, including collagen, herbal extracts, oils, and minerals.

R42 Group is a venture fund and an institute which invents, invests and informs covering AI, deep science, 5G mobile, biotech and fintech.

Investment focus

Biotechnology, Health Care, Information Technology
Seed, Funding Round, Pre-Seed
United Kingdom, United States, Austria

Portfolio highlights

Healx — At Healx we use AI drug discovery to develop new treatments for rare diseases. We bring treatments from prediction to patient.
xWatts — xWatts is an intelligent energy management software that reduces energy costs and emissions in commercial buildings.
Senisca — Developing a new generation of senotherapeutic interventions to target the diseases and aesthetic signs of ageing.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Investment focus

Health Care, Artificial Intelligence, Software
Seed, Pre-Seed, Series A
United States, United Kingdom, Austria

Portfolio highlights

Noah Labs — Noah Labs is a compant that creates AI-powered software solutions for medical care and research that help diagnose, manage illnesses, and guide interventions.
Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
Lillian Care — Lillian is building a nationwide network of health facilities in Germany.

Independent Corporate Finance Advisors & Private Equity Investors

Investment focus

Health Care, Life Science, Biotechnology
Seed, Series A, Funding Round
United Kingdom

Portfolio highlights

Neurovalens — Neurovalens delivers innovative solutions in the field of neuroscience, bioscience and neurophysiology.Neurovalens has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme. The project, recorded on the ERDF beneficiaries’ website, will be implemented over the next one year, undertaking research anddevelopment activities aimed at improving the competitiveness of the business.

Investors by industry